Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Target therapies nel tumore al polmone ALK-positivo: gestione del trattamento nei centri di oncologia del LazioIncontro di approfondimento e confronto sulla gestione dei pazienti e sulla strategia terapeutica nei carcinomi polmonari positivi
A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed | BMC Cancer | Full Text
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC | British Journal of Cancer
Un anno di immunoterapia nell'NSCLC - OncoInfo
First-Line ALK+ mNSCLC Clinical Trial - ALECENSA® (alectinib)
ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC - Visualmed
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC - JTO Clinical and
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung
![VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).](https://pbs.twimg.com/media/E3DC69PWQAA80Nz.jpg "VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).")
VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
View of Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor | AboutOpen
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
J-ALEX: Phase III Trial of Alectinib versus Crizotinib - ppt download
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanc
Analisi costo-efficacia di alectinib versus crizotinibnel trattamento di prima linea del carcinoma polmonarenon a piccole cellule (NSCLC) avanzatoper la chinasi del linfoma anaplastico (ALK) positivo | Giornale Italiano di Farmacia Clinica -
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial - Journal of Thoracic Oncology
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Cancers | Free Full-Text | Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
novembre 2017 - Alectinib è superiore a crizotinib in prima linea nei pazienti con NSCLC ALK traslocato
CONVERT trial<br />Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurre
